CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Vitamin D3Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (13)


Name (Synonyms) Correlation
drug850 Ddrops® products, 50,000 IU, Oral Wiki 0.41
drug2761 Support treatment Wiki 0.41
drug3084 Vitamin B12 Wiki 0.41
drug3152 Zinc Citrate Wiki 0.41
drug2437 Resveratrol Wiki 0.41
drug1402 Inactivated convalescent plasma Wiki 0.41
drug1349 ID NOW vs. Accula Wiki 0.41
drug923 Doxycycline Hcl Wiki 0.41
drug3085 Vitamin C Wiki 0.24
drug3150 Zinc Wiki 0.15
drug1489 Ivermectin Wiki 0.09
drug313 Azithromycin Wiki 0.07
drug1284 Hydroxychloroquine Wiki 0.04

Correlated MeSH Terms (9)


Name (Synonyms) Correlation
D012877 Skin Manifestations NIH 0.41
D002647 Chilblains NIH 0.24
D014808 Vitamin D Deficiency NIH 0.15
D018450 Disease Progression NIH 0.10
D007249 Inflammation NIH 0.08
D018352 Coronavirus Infections NIH 0.05
D003141 Communicable Diseases NIH 0.03
D007239 Infection NIH 0.02
D045169 Severe Acute Respiratory Syndrome NIH 0.02

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0100512 Low levels of vitamin D HPO 0.15

There are 6 clinical trials

Clinical Trials


1 Improving Vitamin D Status in the Management of COVID-19

A novel coronavirus disease 2019 (COVID-19) outbreak is a global dramatic pandemic that is immeasurably impacting the communities. Due to lack of data, symptomatic management is used for COVID-19 infection including oxygen therapy and mechanical ventilation for those with severe infection. Considering immunomodulatory, anti-inflammatory anti-fibrotic and anti-oxidant actions of vitamin D, it's safety and ease of administration, as well as direct effects of vitamin D on immune cell proliferation and activity, pulmonary ACE2 expression and reducing surface tension, evaluation of vitamin D supplementation as an adjuvant therapeutic intervention could be of substantial clinical and economic significance. High prevalence of vitamin D deficiency in elderly, smokers, patients with chronic diseases and excess uptake by adipose tissue in obesity make investigations of its role as a secondary therapeutic agent in COVID-19 conceivable. It should be necessary to monitor serum 25(OH)D levels in all inpatient and outpatient populations with COVID-19 to identify the importance of maintaining or promptly increasing circulating levels of 25(OH)D into the optimal range of 100-150 nmol/L. The aim of this study is to conduct a double blind, randomized, controlled three weeks clinical trial on the efficacy of vitamin D (daily low dose versus weekly high dose) in COVID-19 patients in order to determine the relationship between baseline vitamin D deficiency and clinical characteristics and to asses patients' response to vitamin D supplementation in week three and determine its association with disease progression and recovery. Subjects who are randomized to high-dose will be asked to take 50,000 IU for two times during the first week and one dose over second and third weeks to quickly raise their serum levels. Subjects in the low-dose arm will take vitamin D 1000 IU daily for three weeks.

NCT04385940 COVID-19 Dietary Supplement: Ddrops® products, 50,000 IU, Oral Dietary Supplement: Vitamin D3

Primary Outcomes

Description: Number of Participants whose symptoms recovered over three weeks

Measure: Symptoms recovery

Time: Time from onset of intervention to day 21

Secondary Outcomes

Description: Number of patients who required hospitalization

Measure: Hospitalization

Time: Between diagnosis and day 21

Description: x 109/L

Measure: Blood white blood cell count (WBC)

Time: At day 0 before starting intervention and day 21 of intervention

Description: If patients required mechanical ventilation at any time after diagnosis

Measure: Duration of mechanical ventilation

Time: Between diagnosis and day 21

Description: Length of stay in hospital (days)

Measure: Duration of hospitalization

Time: Between diagnosis and day 21

Description: Number of patients who required ICU

Measure: Intensive care unit (ICU) admission

Time: Between diagnosis and day 21

Description: Length of stay in ICU

Measure: Duration of ICU stay

Time: Between diagnosis and day 21

Description: mg/L

Measure: Blood C-reactive protein (CRP)

Time: Baseline and day 21

Description: number of lymphocytes in 1 microliter (µL) of blood

Measure: Blood Lymphocyte count

Time: Baseline and day 21

Description: ng/mL

Measure: Blood Ferritin

Time: Baseline and day 21

Description: platelets per microliter of blood

Measure: Blood platelet count

Time: Baseline and day 21

Description: pg/mL

Measure: Blood interleukin-6 (IL-6)

Time: Baseline and day 21

Description: pg/ml

Measure: Blood Tumor Necrosis Factor alpha (TNF)

Time: Baseline and day 21

2 Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 With or Without Vitamin C, a Multi-centre, International, Randomized Trial: The International ALLIANCE Study

COVID-19 is a global pandemic. So far encouraging results have been shown in different parts of the world with the utilisation of hydroxycloroquine, zinc, and azithromycin, and early studies into some of these, plus some with Vitamin C, have also proven beneficial. Vitamin D levels have also been shown to be an important indicator to the severity of symptoms in COVID-19 patients.

NCT04395768 COVID19 Dietary Supplement: Vitamin C Drug: Hydroxychloroquine Drug: Azithromycin Dietary Supplement: Zinc Citrate Dietary Supplement: Vitamin D3 Dietary Supplement: Vitamin B12
MeSH:Disease Progression

Primary Outcomes

Description: Composite measure: Change in severity and duration of symptoms

Measure: Symptoms

Time: once daily for 15 days since enrollment/baseline at admission to hospital

Description: total number of days in hospital since admission

Measure: Length of hospital stay

Time: at 15 and 45 days since admission/ enrolment

Description: need for invasive mechanical ventilation or mortality within 15 days from enrolment

Measure: invasive mechanical ventilation or mortality

Time: any time within 15 days from enrolment

Secondary Outcomes

Description: Death

Measure: Mortality

Time: 15 and 45 days since enrolment

Description: need for and number of days of invasive mechanical ventilation, in case of no need for mechanical ventilation: days=0

Measure: mechanical ventilation

Time: at 15 and 45 days since enrolment

Description: need for and number of days for humidified high-flow oxygen

Measure: oxygen

Time: 15 and 45 days since enrolment

Description: admission to ICU (intensive care unit)

Measure: ICU

Time: 15 and 45 days since enrolment

Description: days in hospital

Measure: days in hospital

Time: 15 and 45 days since enrolment

Description: days in ICU

Measure: days in ICU

Time: 15 and 45 days since enrolment

Description: need for and days of renal replacement therapy

Measure: renal replacement therapy

Time: 15 and 45 days since enrolment

Description: need for and days of Extracorporeal support

Measure: Extracorporeal support

Time: 15 and 45 days since enrolment

3 Randomized Double-Blind Placebo-Controlled Proof-of-Concept Trial of Resveratrol for the Outpatient Treatment of Mild Coronavirus Disease (COVID-19)

There is evidence that resveratrol might help fight coronavirus as well as help protect the body from the effects of disease (COVID-19) caused by the infection. In this proof-of-concept pilot study we will compare the effects of resveratrol to placebo to assess the safety of resveratrol and explore effectiveness.

NCT04400890 COVID-19 Drug: Resveratrol Dietary Supplement: Vitamin D3

Primary Outcomes

Description: Proportion of study participants admitted to the hospital within 21 days of testing positive

Measure: Hospitalization rates for COVID-19

Time: 21 days from testing positive from COVID-19

Secondary Outcomes

Description: Proportion of study participants admitted to the ICU within 21 days of testing positive

Measure: ICU Admission Rates

Time: 21 days from testing positive from COVID-19

Description: Proportion of study participants receiving invasive ventilation within 21 days of testing positive

Measure: Invasive Ventilation Rates

Time: 21 days from testing positive from COVID-19

Other Outcomes

Description: Modified BORG scale, visual analog scale for fatigue

Measure: Reported symptom severity

Time: 21 days from testing positive from COVID-19

Description: Diarrhea, nausea, abdominal cramping

Measure: Adverse events

Time: 21 days from testing positive from COVID-19

4 Vitamin D Testing and Treatment for Adults With COVID 19

This study will measure vitamin D levels in adults with COVID 19. Participants with low levels of vitamin D will be entered into an open label trial of supplementation with vitamin D.

NCT04407286 Covid 19 Vitamin D Deficiency Dietary Supplement: Vitamin D3
MeSH:Vitamin D Deficiency
HPO:Low levels of vitamin D

Primary Outcomes

Description: change in level of Vitamin D, 25-Hydroxy between the two time points

Measure: Vitamin D levels

Time: baseline and after two weeks of vitamin D supplementation

Description: We will calculate the change in severity of COVID 19 symptoms from baseline to 2 weeks after vitamin D supplementation

Measure: severity of COVID 19 symptoms

Time: baseline and at 2 weeks after vitamin D supplementation

5 The Effect of Weekly 50,000 IU Vitamin D3 Supplements on the Serum Levels of Selected Cytokines Involved in Cytokine Storm of Covid-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People With Vitamin D Deficiency

The effect of Weekly 50,000 IU vitamin D3 supplements on the serum levels of selected cytokines involved in cytokine storm of Covid-19; A randomized clinical trial in the Covid-19 uninfected people with vitamin D deficiency.

NCT04476745 Cytokine Storm Dietary Supplement: Vitamin D3

Primary Outcomes

Description: seum levels

Measure: IL-1 beta

Time: 8 weeks

Description: serum levels

Measure: IL-6

Time: 8 weeks

Description: serum levels

Measure: TNF

Time: 8 weeks

Secondary Outcomes

Description: ng/ml

Measure: serum concentrations of 25-hydroxyvitamin D

Time: 8 weeks

Other Outcomes

Description: seum levels

Measure: lipid profile parameters

Time: 8 weeks

6 A Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infection

In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months.

NCT04482686 COVID Covid-19 Corona Virus Infection Coronavirus Infection Coronavirus-19 SARS-CoV2 SARS-CoV Infection Drug: Ivermectin Drug: Doxycycline Hcl Dietary Supplement: Zinc Dietary Supplement: Vitamin D3 Dietary Supplement: Vitamin C
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Time to negative RT-PRC result indicating that patient is no longer infective

Measure: Time to Non-Infectivity by RT-PCR

Time: 6 months

Description: Time to reduced symptoms in each treatment group as indicated by NEWS scores, which rate patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk.

Measure: Time to Symptom progression in days as measured by NEWS scoring system (National Early Warning Score)

Time: 6 months

Description: Time to reduced symptoms in each treatment group as indicated by NEWS scores, which rate patient status based on a zero to three scale for 8 parameters. These values are added up to create the NEWS score. The lower the NEWS score, the better the patient's clinical condition. Zero is the lowest possible score, whereas 7 or greater represents a high degree of clinical risk.

Measure: Time to Symptom improvement as measured by NEWS scoring system (National Early Warning Score)

Time: 6 months

Description: Patients will have serum stored for titer testing to compare antibody levels over time

Measure: Efficacy of Treatment as measured by Titer

Time: 6 months

Description: Number of patients testing negative for SARS-CoV-2 by RT-PCR after 10 days of treatment

Measure: Efficacy of Treatment as measured by RT-PCR

Time: 10 days

Secondary Outcomes

Description: Blood D-Dimer levels

Measure: Safety of Treatment as Measured by D-Dimer

Time: 6 Months

Description: Blood Pro-Calcitonin levels

Measure: Safety of Treatment as Measured by Pro-Calcitonin

Time: 6 Months

Description: Blood CRP levels

Measure: Safety of Treatment as Measured by C-Reactive Protein

Time: 6 Months

Description: Blood ferritin levels

Measure: Safety of Treatment as Measured by Ferritin

Time: 6 Months

Description: Blood enzyme levels

Measure: Safety of Treatment as Measured by Liver Enzymes

Time: 6 Months

Description: CBC

Measure: Safety of Treatment as Measured by Complete Blood Count

Time: 6 Months

Description: Blood electrolytes

Measure: Safety of Treatment as Measured by Electrolyte Levels

Time: 6 Months

Description: Presence or absence of Grade 3 or high treatment related adverse events

Measure: Safety of Treatment as Measured by Treatment Related Adverse Events

Time: 6 months


Related HPO nodes (Using clinical trials)